## **Original Article**



International Journal of Women's Health and Reproduction Sciences Vol. x, No. x, xx 2025, x-x

ISSN 2330-4456

# Exploring Sexual Function and its Affecting Factors in Iranian Women with Benign Prostatic Hyperplasia-Afflicted Spouses Referring to Urology Clinics of Shahid Beheshti University of Medical Sciences in Tehran: A Cross-sectional Study



Leila Mohamadkhani Shahri<sup>1,2</sup>, Farzad Allameh<sup>3</sup>, Malihe Nasiri<sup>4</sup>, Zohreh Keshavarz<sup>5\*</sup>

#### Abstract

**Objectives:** Women's sexual function can be significantly affected by the benign prostatic hyperplasia (BPH) of their spouses. Therefore, this study aimed to investigate sexual function and its affecting factors in Iranian women with BPH-afflicted spouses. **Materials and Methods:** The present cross-sectional study included 105 Iranian women with BPH-afflicted spouses. Data were collected using the Female Sexual Functional Index (FSFI), International Prostate Symptoms Score (IPSS), and International Index of Erectile Function (IIEF). Multiple regression was analyzed using SPSS 20 software.

**Results:** The mean age of women and their husbands was  $55.41 \pm 14.19$  and  $61.82 \pm 12.22$ , respectively. As revealed by the results of the multiple linear regression, the variables of female's age (B = -0.266, P < 0.001), male's educational level (B = 3.914, P = 0.004), female's sleep disorder (B = 3.780, P = 0.033), The storage symptom of IPSS (IPSS-S) (B = -0.510, P = 0.005) and IIEF Erectile Function sub-score (IIEF-EF) (B= 4.553, P < 0.001) were the final predictors of their "women's sexual function". ( $R^2 = 0.595$ , ADJ.  $R^2 = 0.579$ , R = 0.772).

Conclusions: The results of the present study confirm the negative effect of BPH on women's sexual function. Given that, the variables of female's age and male's educational level from the socio-demographic factors, female's sleep disorder from the factors related to BPH, IPSS-S from the IPSS and IIEF-EF from the IIEF were the final predictors of "women's sexual function." Therefore, the condition of men's disease has a significant impact on their spouses' sexual function, and thus, it is necessary to support and pay attention to the spouses of patients. In addition, it is essential to incorporate the concept of women's sexual health with BPH-afflicted husbands into health providers' retraining programs.

Keywords: Women's health, Sexual health, Spouses, Prostatic hyperplasia, Lower urinary tract symptoms

## Introduction

Women's sexual dysfunction (WSD) is one of the most important health problems that has been studied as a category of mental disorders in scientific literature. Based on the definition of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), sexual dysfunction (SD) is a heterogeneous group of disorders that is usually associated with a significant clinical disorder in the ability to respond sexually or the sexual experience of a person (1,2). SD in women involves orgasmic dysfunction, pain during intercourse, sexual desire disorder, and sexual arousal disorder (3). A healthy and satisfying sex life is one of the important components of women's well-being (3). Therefore, the occurrence of any disorder in women's sexual function leads to

the occurrence of anxiety, depression, communication breakdown, and disruption in personal relationships (4). In this way, WSD can have a considerable economic burden on society's health system (5). The prevalence of SD varies in different regions of the world. Based on the results in Iran, SD affected about 27.3% of women. Disorder in sexual desire was the most prevalent 35% form of SD, and Pain during intercourse and disorders in sexual orgasm were reported as 35.5% and 20.1%, respectively (6). In the same direction, Safarinejad reported the prevalence rate of WSD as about 25%-63%. in this study, racial, ethnic, and cultural differences and traditions governing the society are demonstrated as factors of the difference in the prevalence of sexual disorders among countries (7). A variety of factors, including mental

Received 23 November 2023, Accepted 17 August 2024, Available online 13 February 2025

<sup>1</sup>Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. <sup>2</sup>Department of Midwifery, Karaj Branch, Islamic Azad University, Karaj, Iran. <sup>3</sup>Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. <sup>4</sup>Department of Basic Sciences, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. <sup>5</sup>Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

## Key Messages

- ► The results of the present study confirm the negative effect of BPH on the sexual function of Iranian women.
- ► The age of the female and the educational level of the male were identified as socio-demographic factors that predicted the sexual function of women with spouses who had BPH
- The sexual function of women with BPH-afflicted spouses was predicted by The IPSS.
- ► The female sleep disorder was identified as one of the factors associated with BPH that predicted the sexual function of women with BPH-afflicted spouses.
- ► The IIEF was used to predict sexual function in women with BPH-afflicted partners.
- ▶ It is advisable to integrate sex counseling into pre- and post-treatment programs, as couples' sexual function is significantly enhanced by appropriate counseling and increased sexual awareness.

health, sexual relationships, partner's sexual function, duration of the relationship, and chronic diseases, can affect women's sexual function (8). Because of some reasons, diseases are important factors in creating sexual problems (9). Chronic diseases not only have a profound effect on patients but also affect their spouses (10). The effect of these diseases is stronger in the patient's wife, and women are more sensitive to the chronic diseases of their husbands (11). According to the evidence, a spouse's illness reduces the quality of life of couples (12). In this regard, Laumann et al found that the probability of SD is higher in women who have not had a proper relationship with their spouses or who have not been able to express their sexual needs (13). Garraway also confirmed the importance of sexual life and sexual activity in patients with prostate symptoms (14). Benign prostatic hyperplasia (BPH) has an important role in couples' sexual health due to its association with SD (15). BPH, as one of the most common causes of lower urinary tract symptoms (LUTS), can lead to difficulty in urinating, urgency with leaking or dribbling, and nocturia, and also can impact quality of life (QOL), impair sexual function (16). BPH-related LUTS have been linked to SD. Erectile dysfunction (ED) and ejaculatory dysfunction (EjD) are two types of SD (17). ED has a significant impact on the physical and mental health (18), sexual function, and marital relationships of couples (19). Based on the evidence, the burden of LUTS goes beyond the affected person. The wives of men with BPH also suffer from significant complications, the most prevalent of which include psychological burden, inadequate sex life, and sleep disorder, which can be attributed to the symptoms of nocturia frequency and urgency/ urge incontinence (20). Sells et al also found that 66% of women with BPH-afflicted spouses experienced a worsened sex life (21). On the other hand, despite the high prevalence of SD in couples with BPH-afflicted and requiring treatment, sexual adverse events (AEs) of the treatments are not sufficiently evaluated, and AEs can negatively impact their QOL by causing SD (22). Given the fact that in the Iranian family culture, the marital sexual relationship is a completely personal and private matter, treatment programs and medical and care follow-ups of patients are often not discussed (23). Additionally, it is important to acknowledge that women's attitudes toward sex are incorrect in numerous cultures. Consequently, they refrain from discussing their issues, although they have numerous issues (24). Moreover, the desire to have sexual relationships by women through requesting or showing interest is considered inappropriate. Also, the husband's preferences and satisfaction with sexual relationships are considered more important than the wife's (25). Additionally, the role of the spouse is still ignored by urologists (26). However, it is important to note that male-origin SD in marital life can be treated more successfully when it finds a couple's identity (27). And so, in a holistic approach, the central role of the sexual partner is considered for evaluation and treatment (28). Unfortunately, the high prevalence of BPH in Iran (29) has imposed a heavy burden of the disease on the health system, and it will increase health-related costs (30). Despite the high prevalence of sexual disorders in women, not much attention has been paid to them, and few of these women seek medical treatment (31). Social, cultural, and economic factors are involved in referring these people to treatment, and the lack of proper treatment leads to the chronicity of symptoms and the development of mental disorders and finally deprives the couple of peace and comfort (13). The sexual health of women whose partners suffer from BPH requires particular attention. Therefore, there was a need to conduct a cross-sectional study to determine the status of sexual function and its affecting factors in Iranian women with BPH-afflicted spouses.

## **Patients and Methods**

## Study Design and Participants

The current research was based on the STROBE checklist, which is a tool for evaluating the quality of observational studies (32). The participants were women with BPH-affected spouses whose BPH was diagnosed by referring couples to Urology clinics of hospitals affiliated with Shahid Beheshti University of Medical Sciences in Tehran from September 7, 2022, to March 19, 2023, according to their medical history, clinical examinations, and paraclinical findings.

## Inclusion and Exclusion Criteria

Inclusion criteria were the completion of the informed consent form by couples, Iranian couples with 40-year-old and older BPH-afflicted spouses, literacy, the diagnosis of the disease by a urologist (Diagnosis BPH included 1-Digital rectal examination (DRE); 2- Laboratory studies including urinalysis, urine culture, prostate-specific antigen (PSA); 3- Ultrasonography [abdominal,

renal, transrectal]) (33), the patient that was undergoing expectant treatment or drug therapy, being not candidates for surgery or being in post-surgery period, and no history of acute or chronic physical diseases such as diabetes, heart disease, kidney disease, addiction, connective tissue diseases and the use of drugs that affect sexual activity (such as antidepressants, neurological and antipsychotics), according to the couples themselves. The exclusion criteria included the couples' unwillingness to attend and continue the study and not completing the questionnaires completely.

## Sampling

This descriptive-correlational study was conducted in Urology clinics of hospitals affiliated with Shahid Beheshti University of Medical Sciences in Tehran-Iran. Considering  $\alpha$ = 0.05, d=1, and z = 1.96 and based on the standard deviation of the sexual function score obtained from previous studies ( $\sigma$  = 5) (34), the sample size was determined to be 96 couples. Taking into account the probable 10% drop, 105 couples were included in the study using a multi-stage sampling method through the following formula:

$$n = \frac{z_{\frac{\alpha}{2}}^2 \sigma^2}{d^2}$$

To select the sampling locations, first, the Urology clinics of Shahid Beheshti University of Medical Sciences were divided into four categories, and from each category, the clinics with the most referrals were selected. The sample size in each clinic was determined by quota method and taking into account the number of clients (number of samples in Imam Hossein Hospital Clinic = 10, Shohadae-Tajrish Hospital Clinic=55, Shahid Labbafi Nezhad Hospital Clinic = 22 and Shahid Modaress Hospital Clinic=18) and ultimately, sampling was done in the clinics by using a convenience sampling method. Then, in each clinic, the samples were selected to represent the society as much as possible and appropriate to the research purposes. If one of the couples left the study or did not answer 10% of the questionnaire, the sample was eliminated, and a new couple was replaced.

## Instrument and Measures

The following tools were used in this study:

Socio-demographic questionnaire: It contained 16 questions for women and 27 for men regarding personal and social information and BPH. The validity of the questions was confirmed using content validity and the opinions of 10 professors of obstetrics and urology.

FSFI Questionnaire: This 19-item questionnaire was designed by Rosen et al to measure women's sexual function in six domains, including sexual desire (questions number 1–2), sexual arousal (questions number 3–6), lubrication (questions number 7–10), orgasm (questions

number 11–13), satisfaction (questions number 14–16) and pain (questions number 17–19). The domains are assessed using a response range from zero or one to five, where a score of five indicates better sexual function (1–5 and 0–5 for questions 1–2 and 3–19, respectively). The total score for each individual is calculated by summing the scores from each domain, with a minimum score of 2 and a maximum score of 36. A score below 28 indicates unfavorable sexual function. A score of zero in each domain shows no sexual activity during the last month (last 4 weeks) (35). In Iran, the construct validity of the tool was confirmed through exploratory factor analysis, and its reliability was assessed using the retest method, with an R-value of 0.71 (36).

International Prostate Symptoms Score Questionnaire: The IPSS questionnaire comprises eight questions, seven regarding the symptoms for the preceding last 1 month and one assessing the QOL. The seven questions assessing the symptoms include IPSS-S, the storage or irritative symptom (voiding frequency, urgency, and nocturia), and IPSS-V, the voiding or obstructive symptom (incomplete emptying, intermittency, weak stream, and straining). Each symptom is assigned a score from 0 to 5 for a maximum of 35 points. The scores of these seven questions are added to determine the severity of the patient's urinary symptoms: mild - 0-7, moderate -8-19, and severe - 20-35. The eighth question assesses the quality of life (IPSS-Q) and is assigned a score of 0-6, with 0 and 6 indicating the best and the worst QOL situation, respectively. The tool's validity and reliability have been confirmed by Barry et al (37). Panahi et al have confirmed the tool's validity and reliability in Iran (38).

IIEF Questionnaire: This questionnaire is composed of 15 questions (Q1-15) and five domains: erectile function (Q1-5, 15), orgasmic function (Q9, 10), sexual desire (Q11, 12), intercourse satisfaction (Q6-8), and overall satisfaction domain (Q13, 14) (39,40). A higher score indicates better sexual performance, with a maximum acceptable score of 75, representing the best sexual status across different areas (41). The erectile function domain of the IIEF-15 questionnaire has been validated as a diagnostic tool in the clinical setting for grading degrees of severity of ED and for distinguishing between men with and without ED (39,40). Through the IIEF-15, ED can be classified based on the erectile function (EF) domain as follows: no ED (EF score 26-30), mild ED (EF score 22-25), mild to moderate (EF score 17-21), moderate (EF score 11-16), and severe ED (6-10). The validity and reliability of the original version were confirmed by Rosen et al (41). In Iran, the construct validity and construct reliability of the tool were confirmed by Pakpour et al (42).

## Statistical Analysis

The extracted data were statistically analyzed using SPSS version 20. The regression model's assumptions were initially assessed to evaluate the multiple linear regression

test. To this end, univariate regression was examined where the dependent variable was the score of WSD dimensions, and the variables with a significant level of P < 0.05 were the independent variables that entered the initial multiple linear regression model. Considering that the problem of multicollinearity was not observed between the independent variables and all the conditions of the regression model were met, a Stepwise multiple linear regression test was used.

## **Results**

Analyses were evaluated for 105 couples, and the participation rate was calculated to be 100%. The mean and standard deviation age of women and their husbands were  $55.41 \pm 14.19$  and  $61.82 \pm 12.22$  years, respectively. The demographic characteristics of the research subjects are presented in (Table 1). The mean and standard deviation of the scores of different dimensions of females' sexual function and their sub-scales are shown in (Table 2).

**Table 1.** Variables of the Socio-demographic Factors and Factors Related to BPH in 150 Iranian Women With BPH-Afflicted Spouses

Variables	Mean ± SD/n (%)				
Socio-demographic Factors	1				
Male's age (y)	61.82 ±12.22				
Female's age (y)	$55.41 \pm 14.19$				
Age difference (y)	$9.36 \pm 9.62$				
Male's BMI (kg/m²)	$26.81 \pm 3.13$				
Duration of marriage (y)	$33 \pm 17.56$				
Male' educational level					
Non-academic	73 (69.52)				
Academic	32 (30.47)				
Female's educational level					
Non-academic	61 (58.09)				
Academic	44 (41.90)				
Male's financial situation					
Satisfied	47 (44.8)				
Intermediate	32 (30.5)				
Dissatisfied	26 (24.8)				
Female's financial situation					
Satisfied	49 (46.7)				
Intermediate	31 (29.5)				
Dissatisfied	25 (23.8)				
Male's employment situation					
Employed	72 (68.57)				
Retired	33 (31.42)				
Female's employment situation					
Employed	49 (46.66)				
Housewife and retired	56 (53.33)				
Living in a house					
Yes	90 (85.7)				
No	15 (14.3)				
Type of marriage					
Permanent	87 (82.9)				
Temporary	18(17.1)				
BPH Factors					
Medication use					
Continuous	72 (68.57)				
Drug discontinuance	33 (31.43)				

Table 1. Continued

Year in edication treatment           Type of medication treatment         14 (13.3)           Drug treatment         91 (86.7)           The reason for visiting the doctor         80 (84.8)           Sexual disorders         16 (15.2)           Storage and voiding symptoms         58 (55.2)           No         47 (44.8)           Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (mg/ml)         75.6 ±5.69           Prostate volume at last test (mg/ml)         75.6 ±5.69           Prostate volume at last test (mg/ml)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         78           Yes         36 (30.0)           No         40 (40)           Female's fear of prostate surgery         78           Yes         5 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         78 (71.4)           Yes         5 (51.4)           No         30 (28.6)           Female's fear of prostate cancer         45 (72.4)           Yes         5 (51.4)           No         30 (28.6)           Female's fear of sexual side effects of medication user </th <th>Table 1. Continued</th> <th></th>	Table 1. Continued	
Waiting         14 (13.3)           Drug treatment         91 (86.7)           The reason for visiting the doctor         Sexual disorders           Storage and voiding symptoms         89 (84.8)           Disorder in female's social life         47 (44.8)           Yes         58 (55.2)           No         47 (44.8)           Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (mg/ml.)         7.56 ± 5.69           Prostate volume at last test (mg/ml.)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         42 (40)           Yes         63 (60.0)           No         42 (40)           Female's fear of prostate surgery         Yes           Yes         75 (71.4)           No         69 (55.7)           Male's fear of prostate cancer         Yes           Yes         75 (71.4)           No         59 (56.2)           No         16 (15.2)           Male's fear of prostate cancer         Yes           Yes         89 (84.8)           No         16 (15.2)           <	Variables	Mean ± SD/n (%)
Drug treatment   51 (15.2)  The reason for visiting the doctor  Sexual disorders   16 (15.2)  Storage and voiding symptoms   89 (84.8)  Disorder in female's social life  Yes   58 (55.2)  No   47 (44.8)  Duration of BPH (mon)   69.51 ±67.30  PSA level at the last test (ng/mL)   7.56 ± 5.69  Prostate volume at last test (mg/mL)   85.17 ± 36.23  Age at the onset of the disease (y)   58.2 ± 9.12  Duration of medication use (mon)   12.08 ± 3.48  Male's fear of prostate surgery  Yes   63 (60)  No   42 (40)  Female's fear of prostate surgery  Yes   63 (60)  No   69 (65.7)  Male's fear of prostate cancer  Yes   75 (71.4)  No   30 (28.6)  Female's fear of prostate cancer  Yes   59 (56.2)  No   46 (43.8)  Male's fear of sexual side effects of medication use  Yes   76 (72.4)  No   29 (27.6)  Male's concern about health status  Yes   89 (84.8)  No   16 (15.2)  Female's concern about her husband's health status  Yes   47 (44.8)  No   58 (55.2)  Male's action for treatment of sexual problems  Yes   47 (44.8)  No   64 (61)  Male's depression disorder  Yes   41 (39)  No   64 (61)  Male's depression disorder  Yes   65 (61.9)  No   60 (57.1)  No   62 (59)  Male's sleep disorder  Yes   60 (57.1)  No   45 (42.9)  Female's sleep disorder  Yes   50 (47.6)  No   55 (52.4)  Disorder in male's social life  Yes   50 (47.6)  No   55 (52.4)  Disorder in male's social life  Yes   50 (47.6)  No   55 (52.4)  Disorder in male's social life	Type of medication treatment	
Persistant for visiting the doctor   Sexual disorders   16 (15.2)     Storage and voiding symptoms   29 (84.8)     Disorder in female's social life   Yes   58 (55.2)     No	Waiting	14 (13.3)
Sexual disorders         16 (15.2)           Storage and voiding symptoms         89 (84.8)           Disorder in female's social life         47 (44.8)           Yes         58 (55.2)           No         47 (44.8)           Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (mg/ml)         7.56 ±5.69           Prostate volume at last test (mg/ml)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         42 (40)           Yes         63 (60)           No         42 (40)           Female's fear of prostate surgery         42 (40)           Yes         50 (65.7)           Male's fear of prostate cancer         75 (71.4)           Yes         59 (56.2)           No         40 (43.8)           Male's fear of prostate cancer         45 (72.4)           Yes         59 (56.2)           No         60 (57.1)           Male's fear of sexual side effects of medication user         46 (72.4)           Yes         67 (72.4)           No         16 (27.4)           No         60 (57.1) <td>O .</td> <td>91 (86.7)</td>	O .	91 (86.7)
Storage and voiding symptoms         89 (84.8)           Disorder in female's social life         Yes           Yes         58 (55.2)           No         47 (44.8)           Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (mg/ml.)         7.56 ± 5.69           Prostate volume at last test (mg/ml.)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         42 (40)           Yes         63 (60)           No         42 (40)           Female's fear of prostate surgery         Yes           Yes         36 (43.3)           No         49 (65.7)           Male's fear of prostate cancer         Yes           Yes         57 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         Yes           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use           Yes         46 (43.8)           Male's fear of sexual side effects of medication use           Yes         47 (44.8)           No	0	
Disorder in female's social life         58 (55.2)           No         47 (44.8)           Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (mg/L)         7.56 ± 5.69           Prostate volume at last test (mL)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         63 (60)           No         69 (65.7)           Female's fear of prostate surgery         78           Yes         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer         75 (71.4)           Yes         59 (56.2)           No         30 (28.6)           Female's fear of prostate cancer         75 (71.4)           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         29 (27.6)           Male's fear of sexual side effects of medication use         Yes           Yes         47 (44.8)           No         16 (15.2)           Female's concern about health status		
Yes         58 (55.2)           No         47 (44.8)           Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (mg/mL)         7.56 ± 5.69           Prostate volume at last test (mL)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         42 (40)           Female's fear of prostate surgery         42 (40)           Female's fear of prostate surgery         42 (40)           Female's fear of prostate cancer         75 (71.4)           No         30 (28.6)           Male's fear of prostate cancer         75 (71.4)           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         75 (57.4)           Yes         75 (75.2)           No         46 (43.8)           Male's fear of sexual side effects of medication user           Yes         76 (72.4)           No         29 (27.6)           Male's concern about health status           Yes         46 (43.8)           No         16 (15.2)           Female's concern about her husband's health status <tr< td=""><td></td><td>89 (84.8)</td></tr<>		89 (84.8)
No         47 (44.8)           Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (ng/mL)         7.56 ± 5.69           Prostate volume at last test (mL)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         18.08 ± 3.48           Male's fear of prostate surgery         42 (40)           Female's fear of prostate surgery         42 (40)           Female's fear of prostate cancer         49 (65.7)           Male's fear of prostate cancer         75 (71.4)           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         79 (56.2)           Yes         75 (71.4)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         29 (27.6)           Male's fear of sexual side effects of medication use         Yes           Yes         46 (43.8)           Male's concern about health status         Yes           Yes         47 (47.4)           No         16 (15.2)           Female's action for treatment of sexual problems         Yes <td></td> <td></td>		
Duration of BPH (mon)         69.51 ±67.30           PSA level at the last test (ng/mL)         7.56 ± 5.69           Prostate volume at last test (mL)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         Yes         63 (60)           No         42 (40)           Female's fear of prostate surgery         Yes         36 (43.3)           No         69 (65.7)         46 (43.3)           No         69 (65.7)         46 (43.3)           No         69 (65.7)         46 (43.8)           Male's fear of prostate cancer         Yes         75 (71.4)           Yes         59 (56.2)         40.0           No         46 (43.8)         40.0           Male's fear of prostate cancer         Yes         76 (72.4)           No         40 (43.8)         40.0           Male's fear of prostate cancer         Yes         76 (72.4)           No         40 (72.4)         40.0           No         40 (72.4)         40.0           No         40 (72.4)         40.0           No         40 (72.4)         40.0		
PSA level at the last test (ng/ml.)         7.56 ± 5.69           Prostate volume at last test (ml.)         85.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         42 (40)           Yes         36 (43.3)           No         69 (65.7)           Male's fear of prostate surgery         75 (71.4)           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         75 (71.4)           Yes         75 (71.4)           No         46 (43.8)           Male's fear of prostate cancer         Yes           Yes         76 (72.4)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         15.2           Male's concern about health status         Yes           Yes         49 (84.8)           No         15.2           Male's action for treatment of sexual problems         Yes           Yes         47 (44.8)           No         41 (39)           No         41		, ,
Prostate volume at last test (ml.)         58.17 ± 36.23           Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         63 (60)           No         42 (40)           Female's fear of prostate surgery         42 (40)           Yes         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer         75 (71.4)           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         75 (71.4)           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         29 (27.6)           Male's concern about health status         Yes           Yes         46 (43.8)           No         16 (15.2)           Female's concern about her husband's health status         Yes           Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         Yes           Yes         41 (39)           No		
Age at the onset of the disease (y)         58.2 ± 9.12           Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         Yes         63 (60)           No         42 (40)           Female's fear of prostate surgery         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         75 (71.4)           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         29 (27.6)           Male's concern about health status         Yes           Yes         46 (43.8)           No         16 (15.2)           Female's concern about health status         Yes           Yes         47 (44.8)           No         47 (44.8)           No         58 (55.2)           Male's concern about her husband's health status           Yes         47 (44.8)           No         61 (58.1)           No         61 (58.1)           No         61 (58.1)		
Duration of medication use (mon)         12.08 ± 3.48           Male's fear of prostate surgery         42 (40)           Female's fear of prostate surgery         42 (40)           Female's fear of prostate surgery         42 (40)           Yes         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer         75 (71.4)           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         59 (56.2)           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         76 (72.4)           Yes         76 (72.4)           No         29 (27.6)           Male's concern about health status         89 (84.8)           Yes         89 (84.8)           No         16 (15.2)           Female's concern about her husband's health status         44 (44.8)           Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         44 (41.9)           Yes         44 (41.9)           No         61 (58.1)           Female's actions for treatment of sexual problems         44 (41.9)	, ,	
Male's fear of prostate surgery         63 (60)           No         42 (40)           Female's fear of prostate surgery         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer	,	
Yes         63 (60)           No         42 (40)           Female's fear of prostate surgery         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer         Yes           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         Yes           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         29 (27.6)           Male's fear of sexual side effects of medication use         Yes           Yes         46 (43.8)           No         16 (15.2)           Female's concern about health status         Yes           Yes         47 (44.8)           No         16 (15.2)           Female's concern about her husband's health status         Yes           Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         Yes           Yes         41 (39)           No         61 (58.1)           Male's depression disorder         Yes           Yes	, ,	12.00 ± 3.40
No         42 (40)           Female's fear of prostate surgery         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer         75 (71.4)           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         Yes           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         29 (27.6)           Male's concern about health status         Yes           Yes         89 (84.8)           No         16 (15.2)           Female's concern about her husband's health status         Yes           Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         Yes           Yes         44 (41.9)           No         61 (58.1)           Female's actions for treatment of sexual problems         Yes           Yes         41 (39)           No         64 (61)           Male's depression disorder         Yes           Yes         65 (61.9)           No		63 (60)
Female's fear of prostate surgery         36 (43.3)           No         69 (65.7)           Male's fear of prostate cancer         75 (71.4)           Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         Yes           Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes           Yes         76 (72.4)           No         29 (27.6)           Male's concern about health status         Yes           Yes         89 (84.8)           No         16 (15.2)           Female's concern about her husband's health status         Yes           Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         Yes           Yes         44 (41.9)           No         64 (61.58.1)           Female's actions for treatment of sexual problems         Yes           Yes         41 (39)           No         64 (61.9)           No         40 (38.1)           Female's depression disorder         Yes           Yes         43 (41)           No <td></td> <td></td>		
Yes       36 (43.3)         No       69 (65.7)         Male's fear of prostate cancer       75 (71.4)         No       30 (28.6)         Female's fear of prostate cancer       Yes         Yes       59 (56.2)         No       46 (43.8)         Male's fear of sexual side effects of medication use       Yes         Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       Yes         Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       Yes         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       Yes         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from affilted-BPH husband         Yes       60 (57.1)         No       62 (59)     <		(.0)
No       69 (65.7)         Male's fear of prostate cancer       75 (71.4)         No       30 (28.6)         Female's fear of prostate cancer       79 (56.2)         No       46 (43.8)         Male's fear of sexual side effects of medication use       46 (72.4)         Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       47 (44.8)         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from affilted-BPH husband         Yes       43 (41)         No       62 (59)         Male's sleep disorder         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder         Yes       50 (47.6)         No       50 (47.6)         No		36 (43.3)
Male's fear of prostate cancer       75 (71.4)         No       30 (28.6)         Female's fear of prostate cancer       59 (56.2)         No       46 (43.8)         Male's fear of sexual side effects of medication use       Yes         Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       Yes         Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       Yes         Yes       47 (44.8)         No       46 (55.2)         Male's action for treatment of sexual problems       Yes         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from affitzed-BPH husband         Yes       43 (41)         No       60 (57.1)         No       60 (57.1)         No       45 (42.9)         Female's sleep disorder		
Yes         75 (71.4)           No         30 (28.6)           Female's fear of prostate cancer         Yes         59 (56.2)           No         46 (43.8)           Male's fear of sexual side effects of medication use         Yes         76 (72.4)           No         29 (27.6)           Male's concern about health status         Yes         89 (84.8)           No         16 (15.2)           Female's concern about her husband's health status         Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         Yes         44 (41.9)           No         61 (58.1)         Female's actions for treatment of sexual problems         Yes         41 (39)           Yes         41 (39)         40 (41)         40 (41)           Male's depression disorder         Yes         65 (61.9)         40 (38.1)           Female's feeling embarrassed and ashamed from afflicted-BPH husband yes         43 (41)         40 (38.1)           Female's sleep disorder         Yes         60 (57.1)         40 (42.9)           Male's sleep disorder         Yes         60 (57.1)         40 (42.9)           Female's sleep disorder         Yes         50 (47.6)         50 (47.6)         50 (47.6) </td <td>Male's fear of prostate cancer</td> <td></td>	Male's fear of prostate cancer	
Female's fear of prostate cancer         Yes       59 (56.2)         No       46 (43.8)         Male's fear of sexual side effects of medication use       Yes         Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       Yes         Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       Yes         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       Yes         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afficted-BPH husband         Yes       43 (41)         No       62 (59)         Male's sleep disorder         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       <	Yes	75 (71.4)
Yes       59 (56.2)         No       46 (43.8)         Male's fear of sexual side effects of medication use       Yes         Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       Yes         Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       Yes         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       Yes         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)	No	30 (28.6)
No       46 (43.8)         Male's fear of sexual side effects of medication use       76 (72.4)         Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       89 (84.8)         Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       Yes         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       Yes         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's soci	Female's fear of prostate cancer	
Male's fear of sexual side effects of medication use       76 (72.4)         Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       39 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       44 (41.9)         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       41 (39)         No       64 (61)         Male's depression disorder       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband       48 (41.9)         No       42 (59)         Male's sleep disorder       45 (42.9)         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       50 (47.6)         No       55 (52.4)         Disorder in male's social life       74 (70.5)	Yes	59 (56.2)
Yes       76 (72.4)         No       29 (27.6)         Male's concern about health status       89 (84.8)         Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       Yes         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       Yes         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband afflicted-BPH husband afflicted-BPH husband afflicted-BPH husband afflicted-BPH husband afflicted-BPH husband afflicted-BPH afflicte	No	46 (43.8)
No         29 (27.6)           Male's concern about health status         89 (84.8)           Yes         89 (84.8)           No         16 (15.2)           Female's concern about her husband's health status         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         44 (41.9)           Yes         44 (41.9)           No         61 (58.1)           Female's actions for treatment of sexual problems         Yes           Yes         41 (39)           No         64 (61)           Male's depression disorder         Yes           Yes         65 (61.9)           No         40 (38.1)           Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes         43 (41)           No         62 (59)           Male's sleep disorder         Yes           Yes         60 (57.1)           No         45 (42.9)           Female's sleep disorder         Yes           Yes         50 (47.6)           No         55 (52.4)           Disorder in male's social life         74 (70.5)	Male's fear of sexual side effects of medication use	
Male's concern about health status         Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       Yes         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       Yes         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband       Yes         Yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life       Yes         Yes       74 (70.5)	Yes	76 (72.4)
Yes       89 (84.8)         No       16 (15.2)         Female's concern about her husband's health status       47 (44.8)         Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       41 (39)         Yes       44 (61)         Male's depression disorder       40 (38.1)         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life       Yes (74.70.5)	No	29 (27.6)
No         16 (15.2)           Female's concern about her husband's health status         47 (44.8)           Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         44 (41.9)           No         61 (58.1)           Female's actions for treatment of sexual problems         41 (39)           No         64 (61)           Male's depression disorder         40 (38.1)           Yes         65 (61.9)           No         40 (38.1)           Female's feeling embarrassed and ashamed from afflicted-BPH husband         Yes           No         43 (41)           No         62 (59)           Male's sleep disorder         Yes         60 (57.1)           No         45 (42.9)           Female's sleep disorder         Yes         50 (47.6)           No         55 (52.4)           Disorder in male's social life         Yes         74 (70.5)	Male's concern about health status	
Female's concern about her husband's health status           Yes         47 (44.8)           No         58 (55.2)           Male's action for treatment of sexual problems         44 (41.9)           No         61 (58.1)           Female's actions for treatment of sexual problems         41 (39)           No         64 (61)           Male's depression disorder         Yes           Yes         65 (61.9)           No         40 (38.1)           Female's feeling embarrassed and ashamed from afflicted-BPH husband         Yes           Yes         43 (41)           No         62 (59)           Male's sleep disorder         Yes           Yes         60 (57.1)           No         45 (42.9)           Female's sleep disorder         Yes           Yes         50 (47.6)           No         55 (52.4)           Disorder in male's social life         Yes (74.70.5)	Yes	89 (84.8)
Yes       47 (44.8)         No       58 (55.2)         Male's action for treatment of sexual problems       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life       Yes (74.70.5)		16 (15.2)
No         58 (55.2)           Male's action for treatment of sexual problems         44 (41.9)           Yes         44 (58.1)           Female's actions for treatment of sexual problems         41 (39)           No         64 (61)           Male's depression disorder         40 (38.1)           Yes         65 (61.9)           No         40 (38.1)           Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes         43 (41)           No         62 (59)           Male's sleep disorder         Yes           Yes         60 (57.1)           No         45 (42.9)           Female's sleep disorder         Yes           Yes         50 (47.6)           No         55 (52.4)           Disorder in male's social life         74 (70.5)		
Male's action for treatment of sexual problems         Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems         Yes       41 (39)         No       64 (61)         Male's depression disorder         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband         Yes       43 (41)         No       62 (59)         Male's sleep disorder         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life         Yes       74 (70.5)		
Yes       44 (41.9)         No       61 (58.1)         Female's actions for treatment of sexual problems       Yes         Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life       Yes         Yes       74 (70.5)		58 (55.2)
No         61 (58.1)           Female's actions for treatment of sexual problems           Yes         41 (39)           No         64 (61)           Male's depression disorder         Yes           Yes         65 (61.9)           No         40 (38.1)           Female's feeling embarrassed and ashamed from afflicted-BPH husband yes         43 (41)           No         62 (59)           Male's sleep disorder         Yes         60 (57.1)           No         45 (42.9)           Female's sleep disorder           Yes         50 (47.6)           No         55 (52.4)           Disorder in male's social life         Yes         74 (70.5)	•	44 (41 0)
Female's actions for treatment of sexual problems           Yes         41 (39)           No         64 (61)           Male's depression disorder         40 (38.1)           Yes         65 (61.9)           No         40 (38.1)           Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes         43 (41)           No         62 (59)           Male's sleep disorder         Yes         60 (57.1)           No         45 (42.9)           Female's sleep disorder         Yes         50 (47.6)           No         55 (52.4)           Disorder in male's social life         Yes         74 (70.5)		
Yes       41 (39)         No       64 (61)         Male's depression disorder       Yes         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life       Yes       74 (70.5)		61 (56.1)
No         64 (61)           Male's depression disorder         Fes         65 (61.9)           No         40 (38.1)           Female's feeling embarrassed and ashamed from affilicted-BPH husband Yes         43 (41)           No         62 (59)           Male's sleep disorder         Yes         60 (57.1)           No         45 (42.9)           Female's sleep disorder         Yes         50 (47.6)           No         55 (52.4)           Disorder in male's social life         Yes         74 (70.5)	·	41 (39)
Male's depression disorder         Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life       Yes         74 (70.5)       74 (70.5)		
Yes       65 (61.9)         No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes         Yes       43 (41)         No       62 (59)         Male's sleep disorder       Yes         No       45 (42.9)         Female's sleep disorder         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life         Yes       74 (70.5)		04 (01)
No       40 (38.1)         Female's feeling embarrassed and ashamed from afflicted-BPH husband Yes       43 (41)         No       62 (59)         Male's sleep disorder       Ves         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder       Yes         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life       Yes         Yes       74 (70.5)	•	65 (61.9)
Female's feeling embarrassed and ashamed from afflicted-BPH husband         Yes       43 (41)         No       62 (59)         Male's sleep disorder       Ves         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life         Yes       74 (70.5)		, ,
Yes     43 (41)       No     62 (59)       Male's sleep disorder       Yes     60 (57.1)       No     45 (42.9)       Female's sleep disorder       Yes     50 (47.6)       No     55 (52.4)       Disorder in male's social life       Yes     74 (70.5)		
Male's sleep disorder         Yes       60 (57.1)         No       45 (42.9)         Female's sleep disorder         Yes       50 (47.6)         No       55 (52.4)         Disorder in male's social life         Yes       74 (70.5)		
Yes     60 (57.1)       No     45 (42.9)       Female's sleep disorder     50 (47.6)       Yes     50 (47.6)       No     55 (52.4)       Disorder in male's social life     74 (70.5)	No	
No     45 (42.9)       Female's sleep disorder     50 (47.6)       Yes     50 (47.6)       No     55 (52.4)       Disorder in male's social life       Yes     74 (70.5)	Male's sleep disorder	
Female's sleep disorder  Yes 50 (47.6)  No 55 (52.4)  Disorder in male's social life  Yes 74 (70.5)	Yes	60 (57.1)
Yes 50 (47.6) No 55 (52.4)  Disorder in male's social life Yes 74 (70.5)	No	45 (42.9)
No 55 (52.4)  Disorder in male's social life  Yes 74 (70.5)	Female's sleep disorder	
Disorder in male's social life Yes 74 (70.5)	Yes	50 (47.6)
Yes 74 (70.5)	No	55 (52.4)
, ,	Disorder in male's social life	
	Yes	74 (70.5)
No 31 (29.5)	No	31 (29.5)

Table 2. The Mean (SD) of the FSFI and Their Sub-scales Scores in 150 Iranian Women With BPH-Afflicted Spouses

Variables	Subscales	Mean (SD)	Score out of 100	Range of Scores
	FSFI-D	$3.84 \pm 1.51$	64	1.2-6
	FSFI-A	$3.40 \pm 1.88$	56.66	0-6
FSFI ª	FSFI-L	$3.92 \pm 1.98$	65.33	0-6
	FSFI-O	$2.78 \pm 1.80$	46.33	0-6
	FSFI-S	$4.02 \pm 1.76$	67	0.8-6
	FSFI-P	$3.67 \pm 2.14$	61.16	0-6
	FSFI-T	$21.64 \pm 9.95$	60.11	2-36

FSFI: Female Sexual Function Index; FSFI-A: FSFI Arousal sub-score; FSFI-D: FSFI Desire sub-score; FSFI-L: FSFI Lubrication sub-score; FSFI-O: FSFI Orgasm sub-score; FSFI-P: FSFI Pain sub score: Female's Pain during and following vaginal penetration; FSFI-S: FSFI Satisfaction sub score: Female's satisfaction with the amount of closeness with a partner and sexual relationship and overall sex life; FSFI-T: Total FSFI.

The mean and standard deviation of IPSS and sub-scales are shown in (Table 3). The results of univariate linear regression are also offered in (Table 4). Then, to measure the effect of socio-demographic factors, sexual function of men, and factors related to BPH and IPSS on female sexual function, multiple linear regression was used, and the significant variables of linear regression were entered into the model. Based on the results of multiple regression, 58% of the variance of the overall score of "women's sexual function" could be explained by five predictable variables. Given the fact that ( $R^2 = 0.60$ ), 40% of the changes were affected by factors and variables outside the study and 60% of the remaining changes in "women's sexual function" were caused by the variables considered as independent variables in this study (Table 5).

#### Discussion

This study aimed to investigate the status of sexual function and its affecting factors in Iranian women with BPH-afflicted spouses. SD includes a complex interaction of physiological, psychological, and social factors, and the probability of SD is higher in women who have not had a proper relationship with their spouses or who have not been able to express their sexual needs (13). In line with the study by Mohammad Alizadeh Charandabi et al (43), in the present study, the BPH of men had a significant effect on women's sexual function.

Based on the results of the present study, the variables of female's age and male's educational level from the sociodemographic factors, female's sleep disorder from the factors related to BPH, IPSS-S from the IPSS and IIEF-

Table 3. The mean (SD) of the IPSS with its sub-scales score in 150 Iranian men with BPH- Afflicted

Variables	Subscales	Phrases	Mean ± SD	Score out of 100	Range of Scores	Scoring	No. (%)
		Incomplete bladder emptying	9.60 ± 6.11	48	1-20		
	IPSS-V	Straining					
	1F33-V	Intermittency			1-20		
		Weak stream					
		Frequency		46.13	0-15		
	IPSS-S	Nocturia	$6.92 \pm 4.75$				
		Urgency					
			16.53 ± 10.76	47.22	1-35 - -	Asymptomatic (0)	0 (0)
	IPSS-T					Mildly symptomatic (1-7)	39 (37.1)
IPSS						Moderately symptomatic (8-19)	36 (34.3)
						Severely symptomatic (20-35)	30 (28.6)
		If you were to spend the rest of your life with your prostate symptoms just as they are now, how would you feel about that?	4.06 ± 1.80	67.66	-	Delighted	3 (2.9)
						Pleased	7 (6.7)
						Mostly satisfied	15 (14.3)
	IPSS-Q				0-6ª	Mixed (about equally satisfied and dissatisfied)	15 (14.3)
						Mostly dissatisfied	14 (13.3)
						Unhappy	17 (16.2)
						Terrible	34 (32.4)

IPSS, International Prostate Symptoms Score; IPSS-Q: Quality of Life-IPSS; IPSS-S: The storage (or irritative) symptom; IPSS-T: The total of the (IPSS-S) and the (IPSS-V); IPSS-V: The voiding (or obstructive) symptom.

<sup>&</sup>lt;sup>a</sup> The sexual function of the study women according to the cut-off point of 28 for the whole scale and sub-scales was as follows: sexual desire: 3.3, sexual arousal: 3.4, vaginal lubrication: 3.4, the peak of sexual pleasure: 3.4, sexual satisfaction: 3.8 and pain: 3.8.

a Given that 6 and 0 were the worst and the best quality of life scores, respectively, most men in the study were mostly dissatisfied with their quality of life.

Table 4. Univariate Linear Regression Between Variables of FSFI and the Socio-demographic Factors and Factors Related to BPH IPSS and IIEF

			95 %	% CI
Variables	В	P value	Lower	Upper
Male's age (y)	- 0.470	<0.001 <sup>b</sup>	-0.600	-0.340
Female's age (y)	- 0.464	<0.001 <sup>b</sup>	- 0.567	- 0.361
Age difference (y)	-0.928	0.561	-4.082	2.226
Male's BMI (kg/m²)	-0.482	0.122	-1.096	0.131
Duration of marriage (y)	-0.339	<0.001b	-0.428	-0.251
Male' educational level (non-academic <sup>a</sup> )	7.616	<0.001b	4.026	11.205
Female's educational level (non-academic <sup>a</sup> )	7.880	<0.001b	4.327	11.432
Male's financial situation	10.322	<0.001 <sup>b</sup>	6.316	14.328
Female's financial situation	9.601	<0.001b	5.461	13.740
Male's employment situation(Retired <sup>a</sup> )	2.473	0.208	-1.398	6.345
Female's employment situation (Housewife and retired <sup>a</sup> )	4.091	0.035 ь	0.294	7.888
Living in a house (Yes <sup>a</sup> )	5.083	0.067	-0.359	10.525
Type of marriage (permanent <sup>a</sup> )	7.096	0.005 b	2.150	12.041
Duration of BPH (Mon)	-0.072	<0.001 <sup>b</sup>	-0.097	-0.047
PSA level (ng/mL)	-0.340	0.047 b	-0.675	-0.005
Prostate volume (mL)	-0.144	<0.001 <sup>b</sup>	-0.190	-0.098
Age at the onset of the disease (y)	-0.537	<0.001b	-0.722	-0.351
Duration of medication use (Mon)	-0.297	<0.001b	-0.429	-0.165
Male's fear of prostate surgery (Yes <sup>a</sup> )	3.385	0.088	-0.511	7.281
Female's fear of prostate surgery (Yes <sup>a</sup> )	-3.075	0.134	-7.109	0.958
Male's fear of prostate cancer (Yes a)	5.227	0.014 b	1.066	9.389
Female's fear of prostate cancer (Yes <sup>a</sup> )	4.725	0.015 b	0.934	8.516
Male's fear of sexual side effects medication use (Yes a)	-13.384	<0.001b	-16.835	-9.934
Male's concern about health status (Yes <sup>a</sup> )	-6.495	0.016 b	-11.730	-1.260
Female's concern about her husband's health status (Yes a)	-0.662	0.736	-4.553	3.229
Male's action for treatment of sexual problems (Yes <sup>a</sup> )	0.348	0.861	-3.575	4.270
Female's action for treatment of sexual problems (Yes a)	0.170	0.932	-3.797	4.138
Male's depression disorder (Yes <sup>a</sup> )	9.199	<0.001 <sup>b</sup>	5.641	12.757
Female's feeling embarrassed from husband disease (Yes <sup>a</sup> )	7.355	<0.001b	3.690	11.020
Male's sleep disorder (Yes <sup>a</sup> )	11.459	<0.001 <sup>b</sup>	8.252	14.667
Female's sleep disorder (Yes <sup>a</sup> )	12.197	<0.001b	9.140	15.253
Disorder in male's social life (Yes <sup>a</sup> )	10.709	<0.001 <sup>b</sup>	7.017	14.401
Disorder in female's social life (Yes <sup>a</sup> )	8.211	<0.001b	4.665	11.758
The reason for visiting the doctor (Storage & Voiding <sup>a</sup> )	2.361	0.385	-3.006	7.727
Type of medication treatment (waiting <sup>a</sup> )	-10.681	<0.001b	-15.980	-5.383
Situation of medication use (Continuous <sup>a</sup> )	3.836	0.055	-0.079	7.751
IPSS-V	-1.035	<0.001b	-1.280	-0.789
IPSS-S	-1.302	<0.001 <sup>b</sup>	-1.623	-0.981
IPSS-T	-0.587	<0.001b	-0.727	-0.448
PSS-Q	-3.250	<0.001b	-4.121	-2.378
IIEF-EF	1.519	<0.001b	1.053	1.985
IIEF-IS	2.750	<0.001b	1.764	3.737
IIEF-OF	4.104	<0.001b	2.765	5.442
IIEF-SD	4.961	<0.001 <sup>b</sup>	3.253	6.669
IIEF-OS	7.082	<0.001 <sup>b</sup>	5.951	8.213
IIEF-T	0.701	<0.001 <sup>b</sup>	0.506	0.897

<sup>&</sup>lt;sup>a</sup>Reference group.

 $<sup>^{\</sup>mathrm{b}}$ Estimated unstandardized regression coefficients with 95% CI; P < 0.05 is significant

Table 5. Multivariable Linear Regression Between the Variables FSFI and the Socio-demographic Factors and Factors Related to BPH IPSS and IIEF

Model <sup>a</sup>		В	SE	Beta <sup>b</sup>	P Value -	95% CI	
						Lower	Upper
Constant		32.393	5.345		< 0.001	21.789	42.996
T 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Female's age	- 0.266	0.059	- 0.380	< 0.001	- 0.384	-0.149
The Socio-demographic factors	Male's educational level	3.914	1.342	0.197	0.004	1.253	6.576
IPSS	IPSS-S	- 0.510	0.176	- 0.244	0.005	-0.859	-0.162
The factors related to BPH	Female's sleep disorder	3.780	1.753	0.191	0.033	0.302	7.257
IIEF	IIEF-EF	4.553	2.192	0.286	< 0.001	2.064	3.725

<sup>&</sup>lt;sup>a</sup> The presented regression model was significant (P < 0.001). Durbin-Watson = 1.634, R<sup>2</sup>= 0.595, ADJ. R<sup>2</sup>=0.579, R=0.772.

EF from IIEF were the final predictors of "women's sexual function."

In the present study, if all variables remained constant, each year of increase in female age decreased the score of "women's sexual function" by 0.266 units. In our study, the highest frequency distribution was 21.9%, which belonged to 50 to 59-year-old women. Graziottin et al also indicated that the SD of women increased with the increase in their age (44). In our study, BPH was added to the main biological factors that cause SD in women and led to the aggravation of this disorder. In the present study, under the condition that all variables remained constant. any increase in the male's educational level increased the score of "women's sexual function" by 3.914 units. In our study, two-thirds of the couples did not have an academic education, and thus, many of their sexual problems were caused by a lack of knowledge, misconceptions, or the inability to express their sexual preferences, and incorrect information about sex (45). As no study was found in this regard, we were content with the results of a study finding a positive relationship between the level of education of women and their sexual function (46). Thus, higher education of men in our study could improve the sexual function of their wives by promoting their knowledge of sexual issues and relationships and understanding of the physical, psychological, and emotional needs of their wives. In our study, under the condition that all variables remained constant, "women's sexual function" with no sleep disorder following BPH-husband was improved approximately by 3.780 units, 47.6% of the women in the present study suffered from sleep disorders, and based on other studies, a significant proportion of the wives of men with LUTS reported sleep disorders and detrimental effects on relationships and sexual activity (20,21). These results are in line with the results of our study. Moreover, physical and mental exhaustion caused by sleep disorder has been mentioned as one of the risk factors for decreased sexual pleasure and SD (47). Finally, for each unit of increase in IPSS-S score, in case all variables remained constant, the score of "women's sexual function" decreased approximately by .510 units. The men's mean score of IPSS-S in the present study was 6.92 and ranged from 0 to

15, and SD increased in some females in the study. Based on the evidence, the burden of LUTS goes beyond the affected person. The wives of men with BPH also suffer from significant complications, the most prevalent of which include psychological burden, inadequate sex life, and sleep disorder, which can be attributed to the symptoms of nocturia frequency and urgency/ urge incontinence (20). In a study similar to the present study, 42% of women were exhausted during the day that was due to waking up at night, and 66% experienced a worsened sex life (21). The present study's findings indicate that, while holding all other variables constant, for every increase in the IIEF-EF score, there was an average increase of 4.553 units in the "women's sexual function" score. Any cause for ED significantly decreases all of the total FSFI score, including sexual desire, arousal, orgasm, and satisfaction of women (48). Mohamadkhani Shahri et al also indicated that ED has a negative effect on sexual quality of life of the patients and their partners as well as on their satisfaction with the relationship (49). In the current study, approximately 45% of men were found to have a low erectile function score. Also, the use of 5α-Reductase Inhibitors (5α-RIs) leads to many men experiencing ED, EjD, and decreased libido (50). Moreover, nocturia also had a direct relationship with ED (51). Thus, ED affects the mental, physical, and sexual health of patients and their wives (52).

## Strengths and Limitations

Despite having several strengths, this study also had some limitations. First of all, examining the women's sexual function was performed at a specific point in time. Also, it was impossible to perform specialized examinations for the presence of mental illnesses and to rely on the participants' self-reports. One of the other limitations of our study was that the study relies on self-reported data, which may introduce recall bias or social desirability bias. In addition, IPSS was associated with some limitations (37). To solve this problem, the urologist performed a complete physical examination, including a DRE, and determined the free and total PSA levels serum and urine analysis to diagnose BPH. Also, the IIEF has potential disadvantages (41). Finally, this study is conducted in an

<sup>&</sup>lt;sup>b</sup> According to the (Beta) value, the age of the female (- 0.380) had the biggest contribution in changing "women's sexual function." Then, the variables IIEF-EF (0.286), IPSS-S (-.244), male's educational level (0.197), and female's sleep disorder had the most significant effects, respectively (0.191).

Iranian population, and cultural factors may influence sexual function and its predictors. The strengths of the study were the use of IIEF (41) and FSFI (35) standard questionnaires.

#### **Conclusions**

Based on the results of the present study, 60% of the changes in "women's sexual function" with BPH-afflicted husbands were caused by the variables of female's age, male's educational level, female's sleep disorder, IPSS-S, and IIEF-EF. Therefore, the condition of men's disease has a significant impact on their spouses' sexual function, and thus, it is necessary to support and pay attention to the spouses of patients. Also, women with BPHafflicted husbands worry about the presence of cancer and the consequences of surgical intervention on them. Consequently, it was suggested in our study that the benign nature of the disease, its effect on sexual function, and the result of different treatment approaches should be discussed in the presence of the patient's spouse. It is strongly recommended that health policymakers in the country prioritize the significance of women's sexual function and its association with the overall health of couples with BPH-afflicted spouses in educational programs. Moreover, it is essential to incorporate the concept of women's sexual health with BPH-afflicted husbands into retraining programs. By doing so, healthcare professionals can enhance their awareness and knowledge regarding sexual health, enabling them to support patients who are BPH-afflicted and their wives better. Finally, considering the high costs of BPH in the future because of the aging population, a systematic management and strategic approach need to be planned for BPH.

## Directions for Future Research

Further studies are warranted in the future to validate the impact of these factors on the sexual function of Iranian women with BPH-afflicted spouses and explore other potential factors influencing it. In addition, this study was conducted as a descriptive study, examining the sexual function of women in Iran at a specific time. Consequently, conducting longitudinal studies would provide more comprehensive insights into the factors influencing the sexual function of these women.

## **Authors' Contribution**

Conceptualization: Leila Mohamadkhani Shahri, Zohreh Keshavarz, Malihe Nasiri.

**Data curation:** Leila Mohamadkhani Shahri, Zohreh Keshavarz, Farzad Allameh.

Formal Analysis: Malihe Nasiri, Zohreh Keshavarz, Farzad Allameh. Funding acquisition: Zohreh Keshavarz, Leila Mohamadkhani Shahri. Investigation: Malihe Nasiri, Farzad Allameh.

**Methodology:** Malihe Nasiri, Farzad Allameh, Leila Mohamadkhani Shahri

Project administration: Leila Mohamadkhani Shahri. Resources: Leila Mohamadkhani Shahri, Zohreh Keshavarz. Supervision: Zohreh Keshavarz.

Validation: Malihe Nasiri, Farzad Allameh.

**Visualization:** Leila Mohamadkhani Shahri, Farzad Allameh, Malihe Nasiri

Writing-original draft: Leila Mohamadkhani Shahri, Zohreh Keshavarz. Writing-review & editing: Leila Mohamadkhani Shahri, Farzad Allameh, Malihe Nasiri, Zohreh Keshavarz.

#### **Conflict of Interests**

Authors declare that they have no conflict of interests.

#### **Ethical Issues**

This study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences in Iran on September 2022-09-06 (Reference no: IR.SBMU.PHARMACY.REC.1401.126). After explaining the study's objectives to the participants and if they were willing to participate and met the inclusion criteria, the researcher completed a written informed consent form for them. The researcher completed all questionnaires in person and two sessions in separate rooms. Also, the participants could withdraw from the study at any stage, and their information remained confidential.

## **Financial Support**

This research has received support from Vice-Chancellor in Research Affairs -Shahid Beheshti University of Medical Sciences.

#### Acknowledgments

This study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences as a part of the Ph.D. thesis of Leila Mohamadkhani Shahri, Ph.D. student of reproductive health at Shahid Beheshti University of Medical Sciences. The authors thank all couples participating in this work and the Vice-Chancellor in Research Affairs -Shahid Beheshti University of Medical Sciences.

#### References

- Vahia VN. Diagnostic and statistical manual of mental disorders
   a quick glance. Indian J Psychiatry. 2013;55(3):220-223. doi:10.4103/0019-5545.117131
- Angel K. The history of 'Female Sexual Dysfunction' as a mental disorder in the 20th century. Curr Opin Psychiatry. 2010;23(6):536-541. doi:10.1097/YCO.0b013e32833db7a1
- Thomas HN, Thurston RC. A biopsychosocial approach to women's sexual function and dysfunction at midlife: a narrative review. Maturitas. 2016;87:49-60. doi:10.1016/j. maturitas.2016.02.009
- 4. Balon R. Burden of sexual dysfunction. J Sex Marital Ther. 2017;43(1):49-55. doi:10.1080/0092623x.2015.1113597
- Goldmeier D, Malik F, Phillips R, Green J. Cost implications of sexual dysfunction: the female picture. Int J Impot Res. 2004;16(2):130-134. doi:10.1038/sj.ijir.3901179
- Ramezani MA, Ahmadi K, Ghaemmaghami A, Azad Marzabadi E, Pardakhti F. Epidemiology of sexual dysfunction in Iran: a systematic review and meta-analysis. Int J Prev Med. 2015;6:43. doi:10.4103/2008-7802.157472
- Safarinejad MR. Female sexual dysfunction in a populationbased study in Iran: prevalence and associated risk factors. Int J Impot Res. 2006;18(4):382-395. doi:10.1038/sj.ijir.3901440
- Sabola NE, Shahin MA, Khader KA, Metwally HM, Desoky MM. Sexual nursing care for the postpartum period and its impact on sexual dysfunction and life satisfaction among Egyptian women. Malays J Public Health Med. 2020;20(2):108-115. doi:10.37268/mjphm/vol.20/no.2/art.491
- Rodin G, Olmsted MP, Rydall AC, et al. Eating disorders in young women with type 1 diabetes mellitus. J Psychosom Res. 2002;53(4):943-949. doi:10.1016/s0022-3999(02)00305-7
- Hagedoorn M, Sanderman R, Ranchor AV, Brilman EI, Kempen GI, Ormel J. Chronic disease in elderly couples: are women more responsive to their spouses' health condition than men? J Psychosom Res. 2001;51(5):693-696. doi:10.1016/s0022-3999(01)00279-3
- 11. Ayles C. Biographical Determinates of Marital Quality.

- London: One Plus One; 2004.
- 12. Balog P. Marital Stress and Cardiovascular Vulnerability [dissertation]. Semmelweis University; 2006.
- 13. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. Jama. 1999;281(6):537-544. doi:10.1001/jama.281.6.537
- Garraway WM, Kirby RS. Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions. Urology. 1994;44(5):629-636. doi:10.1016/s0090-4295(94)80194-0
- Vasquez A. Factors associated with sexual inactivity in patients diagnosed with benign prostatic hyperplasia. J Sex Med. 2023;20(Suppl 1):qdad060.315. doi:10.1093/jsxmed/ qdad060.315
- Giona S, Ganguly I, Muir G. Urologists' attitudes to sexual complications of LUTS/BPH treatments. World J Urol. 2018;36(9):1449-1453. doi:10.1007/s00345-018-2283-x
- Chen LK, Lai YW, Chiu LP, Chen SS. Significant relationship between parameters measured by transrectal color Doppler ultrasound and sexual dysfunction in patients with BPH 12 months after TURP. BMC Urol. 2021;21(1):9. doi:10.1186/ s12894-020-00776-2
- Salonia A, Castagna G, Saccà A, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. J Sex Med. 2012;9(10):2708-2715. doi:10.1111/ j.1743-6109.2012.02869.x
- Fisher WA, Eardley I, McCabe M, Sand M. Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization. J Sex Med. 2009;6(11):3111-3124. doi:10.1111/j.1743-6109.2009.01432.x
- Mitropoulos D, Anastasiou I, Giannopoulou C, et al. Symptomatic benign prostate hyperplasia: impact on partners' quality of life. Eur Urol. 2002;41(3):240-245. doi:10.1016/ s0302-2838(02)00041-6
- Sells H, Donovan J, Ewings P, MacDonagh RP. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int. 2000;85(4):440-445. doi:10.1046/j.1464-410x.2000.00525.x
- 22. Giuliano F, Droupy S. [Sexual side effects of pharmacological treatments]. Prog Urol. 2013;23(9):804-810. doi:10.1016/j. purol.2013.01.008
- Sarhadi M, Navidian A, Fasihi Harandy T, Ansari Moghadam AR. Comparing quality of marital relationship of spouses of patients with and without a history of myocardial infarction. Journal of Health Promotion Management. 2013;2(1):39-48. [Persian].
- Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries. BJU Int. 2005;95(4):609-614. doi:10.1111/j.1464-410X.2005.05348.x
- Harirchi I, Montazeri A, Zamani Bidokhti F, Mamishi N, Zendehdel K. Sexual function in breast cancer patients: a prospective study from Iran. J Exp Clin Cancer Res. 2012;31(1):20. doi:10.1186/1756-9966-31-20
- Fisher WA, Meryn S, Sand M. Communication about erectile dysfunction among men with ED, partners of men with ED, and physicians: the Strike Up a Conversation Study (Part II). J Mens Health Gend. 2005;2(3):309.e301-309.e312. doi:10.1016/j. jmhg.2005.06.004
- 27. McCarthy B. Marital sex as it ought to be. J Fam Psychother. 2003;14(2):1-12. doi:10.1300/J085v14n02\_01
- 28. O'Shaughnessy PK, Ireland C, Pelentsov L, Thomas LA, Esterman AJ. Impaired sexual function and prostate cancer: a mixed method investigation into the experiences of men and their partners. J Clin Nurs. 2013;22(23-24):3492-3502. doi:10.1111/jocn.12190
- 29. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.

- Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi:10.3322/caac.20107
- 30. Park S, Ryu JM, Lee M. Quality of life in older adults with benign prostatic hyperplasia. Healthcare (Basel). 2020;8(2):158. doi:10.3390/healthcare8020158
- 31. Bagherzadeh R, Zahmatkeshan N, Gharibi T, et al. Prevalence of female sexual dysfunction and related factors for under treatment in Bushehrian women of Iran. Sex Disabil. 2010;28(1):39-49. doi:10.1007/s11195-010-9149-5
- 32. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/s0140-6736(07)61602-x
- Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol. 2020;204(4):799-804. doi:10.1097/ ju.00000000000001298
- 34. Yim PW, Wang W, Jiang Y, et al. Health-related quality of life, psychological well-being, and sexual function in patients with benign prostatic hyperplasia after prostatic surgery. Appl Nurs Res. 2015;28(4):274-280. doi:10.1016/j.apnr.2015.02.007
- 35. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208. doi:10.1080/009262300278597
- 36. Mohammadi KH, Heydari M, Faghihzadeh S. The Female Sexual Function Index (FSFI): validation of the Iranian version. Payesh. 2008;7(3):269-278. [Persian].
- Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5 Pt 1):1549-1557. doi:10.1016/s0022-5347(17)36966-5
- Panahi A, Bidaki R, Mehraban D, Rezahosseini O. Validity and reliability of Persian version of international prostate symptom score. Galen Med J. 2013;2(1):18-21. doi:10.31661/gmj. v2i1.35
- 39. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226-244. doi:10.1038/sj.ijir.3900857
- Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54(2):346-351. doi:10.1016/s0090-4295(99)00099-0
- Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822-830. doi:10.1016/ s0090-4295(97)00238-0
- 42. Pakpour AH, Zeidi IM, Yekaninejad MS, Burri A. Validation of a translated and culturally adapted Iranian version of the International Index of Erectile Function. J Sex Marital Ther. 2014;40(6):541-551. doi:10.1080/0092623x.2013.788110
- 43. Mohammad Alizadeh Charandabi S, Rezaei N, Hakimi S, Montazeri A, Khatami S, Karimi P. Sexual function of postmenopausal women and its predictive factors: a community-based study in Ilam, Iran, 2011. Iran J Obstet Gynecol Infertil. 2012;15(23):1-9. doi:10.22038/ijogi.2012.5652
- 44. Graziottin A, Serafini A, Palacios S. Aetiology, diagnostic algorithms and prognosis of female sexual dysfunction. Maturitas. 2009;63(2):128-134. doi:10.1016/j. maturitas.2009.04.007
- 45. Warnock JJ. Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment. CNS Drugs. 2002;16(11):745-753. doi:10.2165/00023210-200216110-

00003

- 46. Pérez-López FR, Fernández-Alonso AM, Trabalón-Pastor M, Vara C, Chedraui P. Assessment of sexual function and related factors in mid-aged sexually active Spanish women with the six-item Female Sex Function Index. Menopause. 2012;19(11):1224-1230. doi:10.1097/gme.0b013e3182546242
- 47. Anderson JL. Acknowledging female sexual dysfunction in women with cancer. Clin J Oncol Nurs. 2013;17(3):233-235. doi:10.1188/13.Cjon.233-235
- 48. Meston CM, Bradford A. Sexual dysfunctions in women. Annu Rev Clin Psychol. 2007;3:233-256. doi:10.1146/annurev. clinpsy.3.022806.091507
- 49. Mohamadkhani Shahri L, Allameh F, Nasiri M, Keshavarz Z. Sexual quality of life and its contributory factors in Iranian

- couples with benign prostatic hyperplasia-afflicted spouses: a cross-sectional study. Crescent J Med Biol Sci. 2025;12(1):42-53. doi: 10.34172/cjmb.2024.3001
- Thomas D, Chughtai B, Kini M, Te A. Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opin Emerg Drugs. 2017;22(3):201-212. doi:10.1080/14728214.2017.13 69953
- 51. Ishizuka O, Matsuyama H, Sakai H, et al. Nocturia potentially influences maintenance of sexual function in elderly men with benign prostatic hyperplasia. Low Urin Tract Symptoms. 2013;5(2):75-81. doi:10.1111/j.1757-5672.2012.00173.x
- 52. Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021;80(3):333-357. doi:10.1016/j.eururo.2021.06.007

© 2025 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.